Related Experiment Videos
Thrombolytic therapy: then and now
1Washington University School of Medicine, St. Louis, MO.
Insights
Thrombolytic therapy has revolutionized acute myocardial infarction treatment. While several agents exist, comparative studies show similar efficacy, establishing thrombolysis as the preferred treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Thrombolytic agents, discovered decades ago, have transformed acute myocardial infarction (AMI) care.
- Four agents are approved: streptokinase, urokinase, tissue plasminogen activator (tPA), and anistreplase.
Purpose of the Study:
- To review the current landscape of thrombolytic therapy for AMI.
- To evaluate the efficacy and comparative effectiveness of available thrombolytic agents.
Main Methods:
- Review of clinical studies and large-scale trials evaluating thrombolytic agents for AMI.
- Analysis of various clinical endpoints including mortality, reperfusion, patency, and cardiac function.
Main Results:
- All approved thrombolytic agents effectively dissolve fibrin clots by converting plasminogen to plasmin.
- Comparative studies, including large trials, have not demonstrated significant differences in efficacy among the agents.
- Key endpoints such as mortality, reperfusion, and cardiac function are consistently improved with thrombolytic therapy.
Conclusions:
- Thrombolytic therapy is the established treatment of choice for acute myocardial infarction.
- Despite a lack of consensus on a single superior agent, current options are effective.
- Ongoing research focuses on new agents and optimized dosing regimens.
Abstract:
Although thrombolytic agents were discovered nearly 60 years ago, it is only within the past decade that the clinical use of these agents has revolutionized the treatment of acute myocardial infarction. There are four currently available agents approved for use in treatment of myocardial infarction: streptokinase, urokinase, tissue plasminogen activator, and anistreplase. Although each of these agents works in a unique fashion, the common end point of therapy is the dissolution of a fibrin clot by the conversion of plasminogen to plasmin. A number of clinically measurable end points have been used to determine the effectiveness of these agents in the treatment of acute myocardial infarction, including mortality, reperfusion, patency, left ventricular function, left ventricular volumes, and quantitative creatine kinase isoenzyme analysis. Secondary end points have included bleeding and stroke, as well as recurrent ischemic events. Numerous clinical studies have demonstrated the effectiveness of all of these agents in achieving the desired end points and comparative studies, including several large-scale trials, have failed to differentiate among these agents with regard to efficacy. Newer dosing regimens for currently available thrombolytic agents, as well as new thrombolytic agents, are currently under active investigation and will be the subject of intense research over the next few years. Despite the lack of consensus as to which agent is superior, it is clear that thrombolytic therapy for acute myocardial infarction is the treatment of choice.